Olema Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
OLMA$7.27-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(unaudited)
(Amounts in thousands)
| Nine Months Ended September 30, | ||||
|---|---|---|---|---|
| 2026 · 2025 | ||||
| Cash flows from operating activities: | ||||
| Net loss | $ | (189,888) | $ | (116,390) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation and amortization expense | 315 | 303 | ||
| Non-cash lease expense | 899 | 875 | ||
| Non-cash interest income on marketable securities | (3,367) | (5,135) | ||
| Stock-based compensation expense, including employee stock purchase plan expense | 35,133 | 13,320 | ||
| Loss on sale of equipment | 98 | — | ||
| Change in assets and liabilities: | ||||
| Prepaid expenses and other current assets | 1,675 | (960) | ||
| Other assets and long-term deposits | (716) | (5,649) | ||
| Accounts payable | (8,044) | (1,175) | ||
| Other current liabilities | 25,839 | 7,353 | ||
| Operating lease liabilities | (939) | (931) | ||
| Net cash used in operating activities | (138,995) | (108,389) | ||
| Cash flows from investing activities: | ||||
| Purchase of equipment | (1,121) | — | ||
| Proceeds from sale of equipment | 50 | — | ||
| Maturities of marketable securities | 260,995 | 253,794 | ||
| Purchases of marketable securities | (168,953) | (247,370) | ||
| Net cash provided by investing activities | 90,971 | 6,424 | ||
| Cash flows from financing activities: | ||||
| Issuance of shares under at-the-market offering, net of issuance costs of $40 | 41,918 | — | ||
| Issuance costs for shares issued under private placement | — | (6,514) | ||
| Proceeds from exercise of stock options | 4,675 | 511 | ||
| Proceeds from borrowings under Credit Facility | — | 3,000 | ||
| Proceeds from issuance of common stock under employee stock purchase plan | 652 | 748 | ||
| Net cash provided by / (used in) financing activities | 47,245 | (2,255) | ||
| Net change in cash and cash equivalents | (779) | (104,220) | ||
| Cash and cash equivalents at beginning of period | 48,301 | 139,480 | ||
| Cash and cash equivalents at end of period | $ | 47,522 | $ | 35,260 |
| Supplemental disclosure of non-cash financing activity | ||||
| Exchange of common stock for pre-funded warrants | $ | — | $ | 29,379 |
| Right-of-use asset obtained in exchange for operating lease liabilities | 55 | 896 | ||
| Purchases of property and equipment included in accrued expenses | 404 | — | ||
See accompanying notes to the unaudited condensed consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.